Yale University School of Medicine, New Haven, CT 06520, USA.
Am Fam Physician. 2012 Feb 1;85(3):239-46.
Cardiovascular complications are the most common cause of perioperative morbidity and mortality. Noninvasive stress testing is rarely helpful in assessing risk, and for most patients there is no evidence that coronary revascularization provides more protection against perioperative cardiovascular events than optimal medical management. Patients likely to benefit from perioperative beta blockade include those with stable coronary artery disease and multiple cardiac risk factors. Perioperative beta blockers should be initiated weeks before surgery and titrated to heart rate and blood pressure targets. The balance of benefits and harms of perioperative beta-blocker therapy is much less favorable in patients with limited cardiac risk factors and when initiated in the acute preoperative period. Perioperative statin therapy is recommended for all patients undergoing vascular surgery. When prescribed for the secondary prevention of cardiovascular disease, aspirin should be continued in the perioperative period.
心血管并发症是围手术期发病率和死亡率的最常见原因。非侵入性应激测试很少有助于评估风险,对于大多数患者,没有证据表明冠状动脉血运重建比最佳药物治疗更能预防围手术期心血管事件。可能从围手术期β受体阻滞剂治疗中获益的患者包括患有稳定型冠状动脉疾病和多种心脏危险因素的患者。围手术期β受体阻滞剂应在手术前数周开始,并滴定至心率和血压目标。在心脏危险因素有限的患者中以及在急性术前期间开始治疗时,围手术期β受体阻滞剂治疗的获益和危害平衡要差得多。建议所有接受血管手术的患者进行围手术期他汀类药物治疗。当开处方用于心血管疾病的二级预防时,阿司匹林应在围手术期继续使用。